Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
2 hedge funds and large institutions have $0 invested in Baudax Bio, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 13 closing their positions.
87% less funds holding
Funds holding: 15 → 2 (-13)
100% less capital invested
Capital invested by funds: $74.5K → $0 (-$74.5K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 13
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$17.9K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$16.8K |
| 3 |
VF
Virtu Financial
New York
|
-$16K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$8.67K |
| 5 |
State Street
Boston,
Massachusetts
|
-$4.29K |
BXRX Hedge Fund Activity: Q4 2023 in Review
2 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q4 2023, worth a combined $0 — down 100% from $74.5K a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of BXRX and 0 opened new positions — a net loss of 13 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $17.9K sold.
- 2 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q4 2023, down from 15 in Q3 2023.
- Funds reported $0 of Baudax Bio, Inc. Common Stock stock for Q4 2023, down 100% quarter-over-quarter.
- 0 funds opened new Baudax Bio, Inc. Common Stock positions in Q4 2023 and 13 closed out, a net change of -13 holders.
- The largest Baudax Bio, Inc. Common Stock seller in Q4 2023 was Vanguard Group, an estimated $17.9K sold.
Based on aggregated 13F filings for Q4 2023.